Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China
Shots:
- Sutro to receive $4M as licensing option fee- ~$200M as an option exercise fee- development- regulatory & commercial milestones along with royalties based on sales of STRO-001 in Greater China. BioNova to get STRO-001 from Sutro under clinical & commercial supply agreements
- BioNova gets the option to acquire exclusive rights for the development & commercialization of STRO-001 in Greater China & will lead clinical development- regulatory approval & commercialization of STRO-001 in multiple indications- including NHL- MM & leukemia in the licensed countries
- Sutro will hold development & commercial rights of STRO-001 globally outside of Greater China- including the US
| Ref: PR Newswire | Image: Linkedin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
